FSTX F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company with an advanced pipeline of multiple immuno-oncology programs dedicated to creating a paradigm-shift in cancer therapy.

As of 06/18/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/06/2016
Outstanding shares:  19,365,931
Average volume:  228,668
Market cap:   $173,712,401
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    30315R107
ISIN:        US30315R1077
Sedol:      BMWC5G8
Valuation   (See tab for details)
PE ratio:   -7.93
PB ratio:   5.18
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy